JP2020073561A5 - - Google Patents

Download PDF

Info

Publication number
JP2020073561A5
JP2020073561A5 JP2020001139A JP2020001139A JP2020073561A5 JP 2020073561 A5 JP2020073561 A5 JP 2020073561A5 JP 2020001139 A JP2020001139 A JP 2020001139A JP 2020001139 A JP2020001139 A JP 2020001139A JP 2020073561 A5 JP2020073561 A5 JP 2020073561A5
Authority
JP
Japan
Prior art keywords
amino
oxo
dihydro
phenoxyphenyl
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020001139A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020073561A (ja
JP6985433B2 (ja
Filing date
Publication date
Priority claimed from JP2017562758A external-priority patent/JP6646072B2/ja
Application filed filed Critical
Publication of JP2020073561A publication Critical patent/JP2020073561A/ja
Publication of JP2020073561A5 publication Critical patent/JP2020073561A5/ja
Application granted granted Critical
Publication of JP6985433B2 publication Critical patent/JP6985433B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020001139A 2015-06-03 2020-01-08 チロシンキナーゼ阻害剤 Active JP6985433B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562170547P 2015-06-03 2015-06-03
US62/170,547 2015-06-03
US201562271689P 2015-12-28 2015-12-28
US62/271,689 2015-12-28
JP2017562758A JP6646072B2 (ja) 2015-06-03 2016-06-02 チロシンキナーゼ阻害剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017562758A Division JP6646072B2 (ja) 2015-06-03 2016-06-02 チロシンキナーゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2020073561A JP2020073561A (ja) 2020-05-14
JP2020073561A5 true JP2020073561A5 (enExample) 2020-07-09
JP6985433B2 JP6985433B2 (ja) 2021-12-22

Family

ID=56118090

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017562758A Active JP6646072B2 (ja) 2015-06-03 2016-06-02 チロシンキナーゼ阻害剤
JP2020001139A Active JP6985433B2 (ja) 2015-06-03 2020-01-08 チロシンキナーゼ阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017562758A Active JP6646072B2 (ja) 2015-06-03 2016-06-02 チロシンキナーゼ阻害剤

Country Status (33)

Country Link
US (5) US20180162861A1 (enExample)
EP (3) EP3912979A1 (enExample)
JP (2) JP6646072B2 (enExample)
KR (3) KR102666352B1 (enExample)
CN (2) CN106459049B (enExample)
AU (2) AU2016270973B2 (enExample)
CA (1) CA2987335A1 (enExample)
CL (2) CL2017003073A1 (enExample)
CO (1) CO2017012947A2 (enExample)
CR (1) CR20170593A (enExample)
DK (1) DK3303334T3 (enExample)
DO (1) DOP2017000279A (enExample)
EA (1) EA039006B1 (enExample)
ES (1) ES2878030T3 (enExample)
HK (1) HK1252378A1 (enExample)
HR (1) HRP20211249T1 (enExample)
HU (1) HUE055419T2 (enExample)
IL (2) IL255946A (enExample)
LT (1) LT3303334T (enExample)
MX (2) MX395007B (enExample)
MY (1) MY190548A (enExample)
PE (1) PE20180521A1 (enExample)
PH (2) PH12017502203B1 (enExample)
PL (1) PL3303334T3 (enExample)
PT (1) PT3303334T (enExample)
RS (1) RS62290B1 (enExample)
SG (1) SG10201912443XA (enExample)
SI (1) SI3303334T1 (enExample)
TN (1) TN2017000501A1 (enExample)
TW (2) TWI810582B (enExample)
UA (1) UA124090C2 (enExample)
WO (1) WO2016196840A1 (enExample)
ZA (2) ZA201708667B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104159635B (zh) 2012-02-27 2018-09-25 奥雷制药有限公司 用于耳蜗内递送治疗剂以治疗耳部病症的固体药物植入物
KR102203990B1 (ko) 2012-09-10 2021-01-18 프린시피아 바이오파마, 인코퍼레이티드 키나제 저해제로서의 피라졸로피리미딘 화합물
US10226782B2 (en) 2013-11-29 2019-03-12 Daizo Corporation Content-accommodating container, content-accommodating product using same, discharge product, and discharge device
ES2841248T3 (es) 2014-02-21 2021-07-07 Principia Biopharma Inc Sales y forma sólida de un inhibidor de BTK
EP3233103B1 (en) 2014-12-18 2020-10-14 Principia Biopharma Inc. Treatment of pemphigus
HRP20211249T1 (hr) * 2015-06-03 2021-11-12 Principia Biopharma Inc. Inhibitori tirozin kinaze
MA42242A (fr) 2015-06-24 2018-05-02 Principia Biopharma Inc Inhibiteurs de la tyrosine kinase
CN105753863B (zh) * 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
CN108349940B (zh) * 2015-10-14 2021-08-13 淄博百极常生制药有限公司 布鲁顿酪氨酸激酶抑制剂
KR102391693B1 (ko) 2016-06-29 2022-04-29 프린시피아 바이오파마, 인코퍼레이티드 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴의 변형 방출 제제
EP3487857B1 (en) * 2016-07-25 2021-09-01 Nerviano Medical Sciences S.r.l. Purine and 3-deazapurine analogues as choline kinase inhibitors
JP2020508326A (ja) * 2017-02-24 2020-03-19 ギリアド サイエンシズ， インコーポレイテッド ブルトン型チロシンキナーゼの阻害剤
WO2019208805A1 (ja) * 2018-04-27 2019-10-31 小野薬品工業株式会社 Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
MX2021000925A (es) 2018-07-25 2021-03-31 Novartis Ag Inhibidores de inflamasoma nlrp3.
CA3224985A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
BR112021004730A2 (pt) * 2018-09-13 2021-06-01 Kissei Pharmaceutical Co., Ltd. composto de imidazopiridinona
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
EP4045051A1 (en) 2019-10-14 2022-08-24 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
CN113045484B (zh) * 2019-12-27 2024-01-26 南京药石科技股份有限公司 一种2-氨基-2-(1-甲基-4-哌啶基)丙烷-1-醇的制备方法
CN113149891B (zh) * 2020-01-07 2024-02-02 南京药石科技股份有限公司 一种2-氨基-2-（1-甲基-4-哌啶基）乙醇的制备方法
MX2022008875A (es) 2020-01-20 2022-08-11 Genzyme Corp Inhibidores terapeuticos de tirosina quinasa para esclerosis multiple recidivante (emr).
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021150723A1 (en) 2020-01-22 2021-07-29 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
MX2022012248A (es) * 2020-03-30 2022-10-27 Igia Pharmaceuticals Inc Formulacion pediatrica de inhibidores de tirosina quinasa.
US20230270743A1 (en) * 2020-08-10 2023-08-31 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Use of btk inhibitors in the treatment of diseases
IL299091A (en) 2020-08-14 2023-02-01 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and their medicinal uses
US12064421B2 (en) 2020-11-02 2024-08-20 Boehringer Ingelheim International Gmbh Substituted 1H-pyrazolo[4,3-c]pyridines and derivatives as EGFR inhibitors
MX2023006854A (es) 2020-12-10 2023-07-20 Genzyme Corp Forma cristalina de tolebrutinib, metodo de preparacion y uso de la misma.
US20240051955A1 (en) * 2020-12-23 2024-02-15 Genzyme Corporation 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof
EP4313023A1 (en) 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
US20240217973A1 (en) * 2021-04-16 2024-07-04 Medshine Discovery Inc. Imidazopyridine compounds and use thereof
CN117295735A (zh) 2021-04-23 2023-12-26 杭州领业医药科技有限公司 Tolebrutinib晶型、无定型及其制备方法和用途
WO2022242740A1 (zh) 2021-05-21 2022-11-24 杭州领业医药科技有限公司 Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途
WO2022257845A1 (zh) 2021-06-11 2022-12-15 苏州科睿思制药有限公司 Tolebrutinib的晶型及其制备方法和用途
WO2023280132A1 (zh) * 2021-07-06 2023-01-12 苏州晶云药物科技股份有限公司 氧代二氢咪唑并吡啶类化合物的晶型及其制备方法
CN118302172A (zh) * 2021-09-24 2024-07-05 查德威克·唐纳森 用于通过粘膜递送药物的干粉可发泡制剂
WO2023122072A1 (en) 2021-12-21 2023-06-29 Genzyme Corporation Crystalline forms of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one and salts thereof
EP4490156A1 (en) * 2022-03-09 2025-01-15 Teva Pharmaceuticals International GmbH Solid state forms of tolebrutinib and of tolebrutinib salts
US20230399313A1 (en) * 2022-06-10 2023-12-14 Advenchen Pharmaceuticals, LLC Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers
AU2023294689A1 (en) * 2022-06-14 2025-01-30 Principia Biopharma Inc. Methods of making tolebrutinib
JP2025521510A (ja) * 2022-06-22 2025-07-10 プリンシピア バイオファーマ インコーポレイテッド 改変されたｂｔｋ阻害剤の作製方法
MA71327A (fr) 2022-06-30 2025-04-30 Principia Biopharma Inc. Inhibiteurs thérapeutiques de tyrosine kinase pour le traitement de la sclérose en plaques et de la myasthénie gravis
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
US20240173313A1 (en) 2022-10-11 2024-05-30 Genzyme Corporation Therapeutic tyrosine kinase inhibitors for multiple sclerosis
WO2024099242A1 (zh) * 2022-11-07 2024-05-16 天津征程医药科技有限公司 氘代的氨基吡啶衍生物以及包含该化合物的药物组合物
US20240238267A1 (en) 2022-12-20 2024-07-18 Genzyme Corporation Drug formulations of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one
EP4658270A2 (en) 2023-02-01 2025-12-10 Principia Biopharma Inc. Methods of diagnosing and treating multiple sclerosis by detecting a biomarker in the cerebrospinal fluid
WO2025188862A1 (en) 2024-03-06 2025-09-12 Principia Biopharma Inc. Methods of making tolebrutinib

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US3760984A (en) 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO2003037890A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
US20060045822A1 (en) 2004-09-01 2006-03-02 Board Of Regents, The University Of Texas System Plasma polymerization for encapsulating particles
CN101056877B (zh) * 2004-09-14 2010-06-09 诺华疫苗和诊断公司 咪唑并喹啉化合物
AU2006213746A1 (en) * 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods
WO2007142755A2 (en) 2006-05-31 2007-12-13 The Regents Of The University Of California Purine analogs
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
SG166093A1 (en) 2006-09-22 2010-11-29 Pharmacyclics Inc Inhibitors of brutonæs tyrosine kinase
AU2010295690B2 (en) 2009-09-16 2016-07-28 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
SG185617A1 (en) * 2010-05-31 2012-12-28 Ono Pharmaceutical Co Purinone derivative
KR102027598B1 (ko) * 2011-05-17 2019-10-01 프린시피아 바이오파마, 인코퍼레이티드 타이로신 키나아제 저해제
AU2012255792A1 (en) * 2011-05-17 2013-11-07 Principia Biopharma Inc. Azaindole derivatives as tyrosine kinase inhibitors
AU2012255759C1 (en) * 2011-05-17 2025-10-23 Principia Biopharma, Inc. Kinase inhibitors
BR112014012727B1 (pt) * 2011-11-29 2022-10-25 Ono Pharmaceutical Co., Ltd Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
EP2861599B1 (en) * 2012-06-18 2019-12-18 Principia Biopharma Inc. Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment of cancer and autoimmune diseases
BR112015000653A2 (pt) 2012-07-11 2019-11-05 Blueprint Medicines Corp compostos inibidores do receptor de fator de crescimento de fibroblasto, sua composição farmacêutica e seus usos
KR102203990B1 (ko) * 2012-09-10 2021-01-18 프린시피아 바이오파마, 인코퍼레이티드 키나제 저해제로서의 피라졸로피리미딘 화합물
US20140142099A1 (en) * 2012-11-20 2014-05-22 Principia Biopharma Inc. Purinone Derivatives as Tyrosine Kinase Inhibitors
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
HRP20211249T1 (hr) * 2015-06-03 2021-11-12 Principia Biopharma Inc. Inhibitori tirozin kinaze
CN105753863B (zh) 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
CN108349940B (zh) 2015-10-14 2021-08-13 淄博百极常生制药有限公司 布鲁顿酪氨酸激酶抑制剂

Similar Documents

Publication Publication Date Title
JP2020073561A5 (enExample)
JP6776399B2 (ja) ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用
JP6218260B2 (ja) Ｊａｋ阻害剤としてのアミノピリミジニル化合物
US7977328B2 (en) Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US8329711B2 (en) Pyridone-substituted-dihydropyrazolopyrimidinone derivative
US7745475B2 (en) Heteroaryl benzamide derivatives as GLK activators
US20100160286A1 (en) Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
JP2019504821A5 (enExample)
JP2009541268A5 (enExample)
US20190345138A1 (en) Heterocyclic amides as kinase inhibitors
CN107872977A (zh) Irak4抑制剂与btk抑制剂的组合产品
US20110053910A1 (en) 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
JP2015500862A5 (enExample)
TW201725202A (zh) 新穎經取代吲唑、其製法、包含其之醫藥製劑及其製備藥劑之用途
US20230092892A1 (en) Amino quinazoline derivatives as p2x3 inhibitors
CA2677572A1 (en) 3-amino-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde derivatives as pkc inhibitors
JP2017052805A5 (enExample)
HUE026041T2 (en) Pyrrolo-triazinone derivatives as P13K inhibitors
JP2009513575A5 (enExample)
US7655652B2 (en) Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation
JP2015527401A5 (enExample)
RU2014152257A (ru) Гетероциклильные пиримидиновые аналоги в качестве ингибиторов tyk2
JP2019523233A5 (enExample)
JP6983945B2 (ja) 自己免疫性疾患の処置
JP2019521167A5 (enExample)